Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
Managing Director, D.E. Shaw and Co., L.P.
Director, Silicon Flatirons Centers' Entrepreneurship Initiative
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Seattle is one of the world’s centers of cancer immunotherapy. Three years ago, Xconomy gathered some of the field’s experts to talk about the promises of harnessing the immune system to fight cancer. Today, some of those promises seem well within reach, and a small but growing number of patients are benefiting from a handful of approved (and expensive) drugs. But while the opportunities seem closer at hand, many challenges remain. It’s time to gather again in Seattle to discuss what’s gone right, what’s gone wrong, and how the field’s brightest minds are working through the obstacles inherent when complicated biology, cutting-edge medical practice, and financial pressures meet.
Hans Bishop, CEO, Juno Therapeutics
Chad Robins, President & CEO, Adaptive Biotechnologies
Brad Gray, CEO, NanoString Technologies
Jill O’Donnell-Tormey, CEO, Cancer Research Institute
Renato Martins, Medical Director, Thoracic/Head and Neck Oncology, University of Washington School of Medicine
Michael Jensen, MD, Director, Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute
Jay Venkatesan, President, Alpine Immune Sciences
Maria Fardis, CEO, Lion Biotechnologies
Andrew Allen, CEO, Gritstone Oncology
Michael Kalos, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Company
Phil Greenberg, Head of the Program in Immunology and member of the Clinical Research Division, Fred Hutch; Professor of Medicine/Oncology and of Immunology, University of Washington
Sylvia Lee, Assistant Member, Clinical Research Division,
Fred Hutchinson Cancer Research Center
Ilya Shmulevich, Professor, Institute for Systems Biology
Richard Maziarz, Medical Director, Adult Blood and Marrow Stem Cell Transplant Program, Oregon Health and Science University
Andrew Albertson, Partner, Fenwick & West
Registration: 12:30 – 1:30 pm
Program: 1:30 – 5:30 pm
Networking Reception: 5:30 – 6:30 pm
Spring Special: $195
Regular Registration: $275
Startup Special: $125
Student Registration: $40
At the Door: $350
Tickets are transferable but not refundable.
Speakers and program schedule are subject to change.